Organon & Co. (OGN)
Automate Your Wheel Strategy on OGN
With Tiblio's Option Bot, you can configure your own wheel strategy including OGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OGN
- Rev/Share 24.4084
- Book/Share 2.1019
- PB 4.7766
- Debt/Equity 16.524
- CurrentRatio 1.6715
- ROIC 0.1476
- MktCap 2609958240.0
- FreeCF/Share 2.2725
- PFCF 4.4539
- PE 3.4519
- Debt/Assets 0.6808
- DivYield 0.0857
- ROE 1.8171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OGN | Evercore ISI | Outperform | In-line | -- | -- | May 2, 2025 |
| Downgrade | OGN | JP Morgan | Neutral | Underweight | $18 | $20 | Sept. 6, 2024 |
News
Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon boasted of a sub-33% dividend payout ratio.
Read More
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN.
Read More
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Organon & Co. (OGN) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Juan Camilo Arjona Ferreira - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan Umer Raffat - Evercore ISI Bhavin Patel - Bank of America Operator Hello, and welcome to the Organon First Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.
Read More
Organon (OGN) Q1 Earnings Surpass Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago.
Read More
Organon Reports Results for the First Quarter Ended March 31, 2025
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports earnings results for Q1 2025, ended March 31, 2025.
Read More
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Why Organon (OGN) Could Beat Earnings Estimates Again
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
Read More
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
About Organon & Co. (OGN)
- IPO Date 2021-05-14
- Website https://www.organon.com
- Industry Drug Manufacturers - General
- CEO Kevin Ali
- Employees 10000